{"retracted":false,"update":{"timestamp":1362528000000,"doi":"10.1007/s00277-013-1713-5","type":"correction"},"doi":"10.1007/s00277-013-1686-4","journal":"Annals of Hematology","publisher":"Springer Nature","title":"Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM"}
